Investing.com - Hims Hers Health (NYSE: HIMS) reported second quarter EPS of $0.06, $0.02 better than the analyst estimate of $0.04. Revenue for the quarter came in at $315.6M versus the consensus estimate of $301.6M.
Guidance
Hims Hers Health sees Q3 2024 revenue of $375.00M-$380.00M versus the analyst consensus of $323.00M.
Hims Hers Health sees FY 2024 revenue of $1.37B-$1.40B versus the analyst consensus of $1.24B.
Hims Hers Health's stock price closed at $17.84. It is up 38.08% in the last 3 months and up 118.65% in the last 12 months.
Hims Hers Health saw 3 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Hims Hers Health's stock price’s past reactions to earnings here.
According to InvestingPro, Hims Hers Health's Financial Health score is "great performance".
Check out Hims Hers Health's recent earnings performance, and Hims Hers Health's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar